Assembly Actions -
Lowercase Senate Actions - UPPERCASE |
|
---|---|
Dec 11, 2015 |
tabled vetoed memo.284 |
Nov 30, 2015 |
delivered to governor |
Jun 24, 2015 |
returned to assembly passed senate substituted for s5170a |
Jun 24, 2015 |
substituted by a7427a |
Jun 11, 2015 |
amended on third reading 5170a |
May 27, 2015 |
advanced to third reading |
May 20, 2015 |
2nd report cal. |
May 19, 2015 |
1st report cal.825 |
May 06, 2015 |
referred to health |
Senate Bill S5170A
Vetoed By Governor2015-2016 Legislative Session
Sponsored By
(R, C, IP) Senate District
Archive: Last Bill Status Via A7427 - Vetoed by Governor
- Introduced
-
- In Committee Assembly
- In Committee Senate
-
- On Floor Calendar Assembly
- On Floor Calendar Senate
-
- Passed Assembly
- Passed Senate
- Vetoed By Governor
- Signed By Governor
Actions
Votes
Bill Amendments
co-Sponsors
(R, C, IP) Senate District
(R, C, G, IP, SC) Senate District
(R, C, IP) 62nd Senate District
(R) Senate District
2015-S5170 - Details
2015-S5170 - Sponsor Memo
BILL NUMBER:S5170 TITLE OF BILL: An act to amend the public health law and the insurance law, in relation to the use of abuse-deterrent technology for opioids as a mechanism for reducing abuse and diversion of opioid drugs PURPOSE: To help prevent the abuse and diversion of opioid analgesic drugs by ensuring that abuse-deterrent drugs approved by the FDA are dispensed whenever prescribed and not substituted by non-abuse deterrent opioids and that that insurance coverage does not disadvantage drugs approved by the FDA as abuse-deterrent. SUMMARY OF PROVISIONS: Section 1 adds a new section 3340 to the Public health law to ensure that an opioid analgesic drug product, brand or generic, with abuse-deterrent technologies is not interchanged or substituted with an opioid analgesic drug product lacking abuse-deterrent technologies without obtaining a new prescription from the provider. Section 2 adds a new section to the insurance law to: ensure that abuse-deterrent opioid products are covered by insurance plans at least the same levels as non-abuse-deterrent opioid products; ensure that a patient is not required to take a non-abuse-deterrent opioid before an abuse-deterrent version; and ensure that prior authorization
2015-S5170 - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 5170 2015-2016 Regular Sessions I N S E N A T E May 6, 2015 ___________ Introduced by Sens. HANNON, AMEDORE, MURPHY, ORTT -- read twice and ordered printed, and when printed to be committed to the Committee on Health AN ACT to amend the public health law and the insurance law, in relation to the use of abuse-deterrent technology for opioids as a mechanism for reducing abuse and diversion of opioid drugs THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. The public health law is amended by adding a new section 3340 to read as follows: S 3340. SUBSTITUTION OF OPIOIDS WITH ABUSE-DETERRENT TECHNOLOGY. 1. NOTWITHSTANDING THE PROVISIONS OF SECTION SIXTY-EIGHT HUNDRED SIXTEEN-A OF THE EDUCATION LAW, NO PHARMACIST SHALL INTERCHANGE OR SUBSTITUTE AN ABUSE-DETERRENT OPIOID ANALGESIC DRUG PRODUCT, BRAND OR GENERIC, WITH AN OPIOID ANALGESIC DRUG PRODUCT LACKING ABUSE-DETERRENT PROPERTIES WITHOUT OBTAINING A NEW PRESCRIPTION FOR A NON-ABUSE DETERRENT OPIOID DRUG FROM THE PRESCRIBER. ANY SUBSTITUTABLE OPIOID DRUG PRODUCT SHALL CONTAIN THE SAME OPIOID ACTIVE PHARMACEUTICAL INGREDIENT AND THE SAME DRUG RELEASE CHARACTERISTICS WITH REGARD TO IMMEDIATE RELEASE, OR EXTENDED RELEASE LONG ACTING PROPERTIES. A DETERMINATION OF INTERCHANGEABILITY BETWEEN TWO ABUSE-DETERRENT OPIOID ANALGESIC DRUG PRODUCTS SHALL NOT REQUIRE THAT BOTH PRODUCTS INCORPORATE THE SAME METHODS OF ABUSE-DETERRENCE, BUT THAT THE OPIOID DRUG PRODUCTS HAVE THE SAME LEVEL OF FDA-APPROVED ABUSE DETERRENCE LABELING CLAIMS. 2. DEFINITIONS. AS USED IN THIS SECTION: (A) "OPIOID ANALGESIC DRUG PRODUCT" MEANS A DRUG IN THE OPIOID ANAL- GESIC DRUG CLASS PRESCRIBED TO TREAT MODERATE TO SEVERE PAIN OR OTHER CONDITIONS, WHETHER IN IMMEDIATE RELEASE OR EXTENDED RELEASE LONG ACTING FORM AND WHETHER OR NOT COMBINED WITH OTHER DRUG SUBSTANCES TO FORM A SINGLE DRUG PRODUCT OR OTHER DOSAGE FORM. EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD08948-03-5
co-Sponsors
(R, C, IP) Senate District
(R, C, G, IP, SC) Senate District
(R, C, IP) 62nd Senate District
(R) Senate District
2015-S5170A (ACTIVE) - Details
2015-S5170A (ACTIVE) - Sponsor Memo
BILL NUMBER:S5170A TITLE OF BILL: An act to amend the public health law and the insurance law, in relation to the use of abuse-deterrent technology for opioids as a mechanism for reducing abuse and diversion of opioid drugs PURPOSE: To help prevent the abuse and diversion of opioid analgesic drugs by ensuring that abuse-deterrent drugs approved by the FDA are dispensed whenever prescribed and not substituted by non-abuse deterrent opioids and that that insurance coverage does not disadvantage drugs approved by the FDA as abuse-deterrent. SUMMARY OF PROVISIONS: Section 1 adds a new section 3340 to the Public health law to ensure that an opioid analgesic drug product, brand or generic, with abuse-deterrent technologies is not interchanged or substituted with an opioid analgesic drug product lacking abuse-deterrent technologies without obtaining a new prescription from the provider. Section 2 adds a new section to the insurance law to: ensure that abuse-deterrent opioid products are covered by insurance plans at least the same levels as non-abuse-deterrent opioid products and ensure that a patient is not required to take a non-abuse-deterrent opioid before an abuse-deterrent version.
2015-S5170A (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 5170--A Cal. No. 825 2015-2016 Regular Sessions I N S E N A T E May 6, 2015 ___________ Introduced by Sens. HANNON, AMEDORE, MURPHY, ORTT, BOYLE, CROCI, GOLDEN, HASSELL-THOMPSON, MARTINS -- read twice and ordered printed, and when printed to be committed to the Committee on Health -- reported favora- bly from said committee, ordered to first and second report, ordered to a third reading, amended and ordered reprinted, retaining its place in the order of third reading AN ACT to amend the public health law and the insurance law, in relation to the use of abuse-deterrent technology for opioids as a mechanism for reducing abuse and diversion of opioid drugs THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. The public health law is amended by adding a new section 3340 to read as follows: S 3340. SUBSTITUTION OF OPIOIDS WITH ABUSE-DETERRENT TECHNOLOGY. 1. NOTWITHSTANDING THE PROVISIONS OF SECTION SIXTY-EIGHT HUNDRED SIXTEEN-A OF THE EDUCATION LAW, NO PHARMACIST SHALL INTERCHANGE OR SUBSTITUTE AN ABUSE-DETERRENT OPIOID ANALGESIC DRUG PRODUCT, BRAND OR GENERIC, WITH AN OPIOID ANALGESIC DRUG PRODUCT LACKING ABUSE-DETERRENT PROPERTIES WHEN THE PRESCRIBER WRITES OR ELECTRONICALLY NOTATES "DISPENSE AS WRITTEN" OR "DAW" ON THE PRESCRIPTION, WITHOUT OBTAINING A NEW PRESCRIPTION FOR A NON-ABUSE DETERRENT OPIOID DRUG FROM THE PRESCRIBER. ANY SUBSTITUTABLE OPIOID DRUG PRODUCT SHALL CONTAIN THE SAME OPIOID ACTIVE PHARMACEUTICAL INGREDIENT AND THE SAME DRUG RELEASE CHARACTERISTICS WITH REGARD TO IMMEDIATE RELEASE, OR EXTENDED RELEASE LONG ACTING PROPERTIES. A DETER- MINATION OF INTERCHANGEABILITY BETWEEN TWO ABUSE-DETERRENT OPIOID ANAL- GESIC DRUG PRODUCTS SHALL NOT REQUIRE THAT BOTH PRODUCTS INCORPORATE THE SAME METHODS OF ABUSE-DETERRENCE, BUT THAT THE OPIOID DRUG PRODUCTS HAVE THE SAME LEVEL OF FDA-APPROVED ABUSE DETERRENCE LABELING CLAIMS. 2. DEFINITIONS. AS USED IN THIS SECTION: (A) "OPIOID ANALGESIC DRUG PRODUCT" MEANS A DRUG IN THE OPIOID ANAL- GESIC DRUG CLASS PRESCRIBED TO TREAT MODERATE TO SEVERE PAIN OR OTHER EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted.
Comments
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.